Tricyclic sesquiterpenes from Vetiveria zizanoides (l.) Nash as antimycobacterial agents

Chemical Biology and Drug Design

Volumn 82, Issue 5, 2013, Pages 587-594

  Dwivedi, Gaurav R ^a   Gupta, Shikha ^a   Roy, Sudeep ^a   Kalani, Komal ^a   Pal, Anirban ^a   Thakur, Jay P ^a   Saikia, Dharmendra ^a   Sharma, Ashok ^a   Darmwal, Nandan S ^b   Darokar, Mahendra P ^a   Srivastava, Santosh K ^a  

^a CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

^b DR RAM MANOHAR LOHIA AVADH UNIVERSITY   (India)

Author keywords

ADME; Antimycobacterial; DNA gyrase inhibition; in vivo toxicity; Khusenic acid; Khusimol; Vetiveria zizanioides

Indexed keywords

ANTIMYCOBACTERIAL AGENT; BACTERIAL DNA; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); KHUSENIC ACID; KHUSIMOL ACID; LOMEFLOXACIN; NALIDIXIC ACID; SESQUITERPENE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BODY WEIGHT; CONTROLLED STUDY; DRUG ISOLATION; FEMALE; IN VITRO STUDY; INTESTINE ABSORPTION; MOUSE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VETIVERIA;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; VETIVERIA ZIZANIOIDES;

ADME; ANTIMYCOBACTERIAL; DNA GYRASE INHIBITION; IN VIVO TOXICITY; KHUSENIC ACID; KHUSIMOL; VETIVERIA ZIZANIOIDES;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BINDING SITES; DNA GYRASE; FEMALE; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PLANT ROOTS; PROTEIN STRUCTURE, TERTIARY; SESQUITERPENES; TOPOISOMERASE II INHIBITORS; TOXICITY TESTS; VETIVERIA;

EID: 84885851875     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12188     Document Type: Article

References (30)

1. World Health Organization. (2012) The burden of disease caused by TB. In: Global tuberculosis report. Sixteen annual WHO reports on TB report 8-28.
2. Ottenhoff T.H.M., Kaufmann S.H.E. (2012) Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog;8:e1002607.
3. Toit L.C., Pillay V., Danckwerts M.P. (2006) Tuberculosis chemotherapy: current drug delivery approaches. Resp Res;7:1-18.
4. Lienhardt C., Cobelens F. (2011) Operational research for TB control: the scope, the needs and the way forward. Int J Tuberc Lung Dis;15:6-13.
5. Negi A.S., Kumar J.K., Luqman S., Saikia D., Khanuja S.P.S. (2010) Antitubercular potential of plants: a brief account of some important molecules. Med Res Rev;30:603-645.
6. Khanuja S.P.S., Srivastava S., Kumar T.R.S., Gupta M.M., Tripathy A.K., Singh M., Bahl J.R., Lal R.K., Darokar M.P., Shasny A.K., Sushil K. (2004) Bioactive hexane fraction from Vetiveria zizanioides. US Patent 6676974.
7. Gupta S., Dwivedi G.R., Srivastava S.K., Darokar M.P. (2012) Antimycobacterial activity of fractions and isolated compounds from Vetiveria zizanoides. Med Chem Res;21:1283-1289.
8. Adams R.P. (1990) Identification of Essential Oils by Ion Trap Mass Spectroscopy. San Diego, CA, USA: Academic Press.
9. Clinical Laboratory Standards Institute (CLSI). (2006a) Performance Standards for Antimicrobial Disk Susceptibility Tests, 9th edn. Approved Standard, M2-A9. CLSI, Wayne, PA.
10. Clinical Laboratory Standards Institute. (2006b) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 7th edn. Approved Standard, M7-A7. CLSI, Wayne, PA.
11. Siddiqi S.H. (1996) BACTEC 460 TB System. Product and Procedure Manual, Revision E. Becton Dickinson Diagnostic Instrument Systems, Maryland, USA.
12. Edwards M.J., Flatman R.H., Mitchenall L.A., Stevenson C.E.M., Maxwell A., Lawson D.M. (2009) Crystallization and preliminary X-Ray analysis of a complex formed between the antibiotic Simocyclinone D8 and the DNA Breakage-Reunion domain of Escherichia Coli DNA Gyrase. Acta Crystallogr Sect F Struct Biol Cryst Commun;65:846-848.
13. Brino L., Urzhumtsev A., Mousli M., Bronner C., Mitschler A., Oudet O., Moras D. (2000) Dimerization of Escherichia coli DNA gyrase B provides a structural mechanism for activating the ATPase catalytic center. J Biol Chem 275: 9468-9475.
14. Saikia D., Parihar S., Chanda D., Ojha S., Kumar J.K., Chanotiya C.S., Shanker K., Negi A.S. (2010) Antitubercular potential of some semisynthetic analogues of phytol. Bioorg Med Chem Lett;20:508-512.
15. Nigam I.C., Komae H. (1967) Essential oils and their constituents. XXXIV. Isolation of khusenic acid and isokhusenic acid from oil of vetiver and some observations concerning their structures. J Pharm Sci;56: 1299-1304.
16. Rao R.C., Serradeil L.G.C., Granger I., Gleye J., Augereau J.M., Bessibes C. (1994) Khusimol, a non-peptide ligand for vasopressin V-1a receptors. J Nat Prod;57: 1329-1335.
17. Copp B.R. (2003) Antimycobacterial natural products. Nat Prod Rep;20:535-557.
18. Zgoda-Pols J.R., Freyer A.J., Killmer L.B., Porter J.R. (2002) Antimicrobial diterpenes from the stem bark of Mitrephora celebica. Fitoterapia;73:434-438.
19. Taniguchi M., Adachi T., Oi S., Kimura A., Katsumura S., Isoe S., Kubo I. (1984) Structure-activity relationship of the Warburgia sesquiterpene dialdehydes. Agric Biol Chem;48:73-78.
20. Galm U., Heller S., Shapiro S., Page M., Li S.-M., Heide L. (2004) Antimicrobial and DNA gyrase-inhibitory activities of novel clorobiocin derivatives produced by mutasynthesis. Antimicrob Agents Chemother;48: 1307-1312.
21. Shen L.L., Pernet A. (1985) Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc Natl Acad Sci USA;82:307-311.
22. Pojer F., Li S.-M., Heide L. (2002) Molecular cloning and sequence analysis of the clorobiocin biosynthetic gene cluster: new insights into the biosynthesis of aminocoumarin antibiotics. Microbiology;148:3901-3911.
23. Oblak M., Kotnik M., Solmajer T. (2007) Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem;14:2033-2047.
24. Brvar M., Perdih A., Hodnik V., Renko M., Anderluh G., Jerala R., Solmajer T. (2012) In silico discovery and biophysical evaluation of novel 5-(2-hydroxybenzylidene) rhodanine inhibitors of DNA gyrase B. Bioorg Med Chem;20:2572-2580.
25. Brvar M., Perdih A., Renko M., Anderluh G., Turk D., Solmajer T. (2012) Structure-based discovery of substituted 4, 5′-bithiazoles as novel DNA gyrase inhibitors. J vMed Chem;55:6413-6426.
26. Minovski N., Vračko M., Solmajer T. (2011) Quantitative structure-activity relationship study of antitubercular fluoroquinolones. Mol Divers;15:417-426.
27. Minovski N., Perdih A., Novic M., Solmajer T. (2013) Cluster-based molecular docking study for in silico identification of novel 6-fluoroquinolones as potential inhibitors against Mycobacterium tuberculosis. J Comput Chem;34:790-801.
28. Lewis R.J., Tsai F.T.F., Wigley D.B. (1996) Molecular mechanisms of drug inhibition of DNA gyrase. BioEssays;18:661-671.
29. Anishetty S., Pulimi M., Pennathur G. (2005) Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis. Comput Biol Chem;29: 68-78.
30. Lakshmi P.T.V., Radhika S., Annamalai A. (2011) Molecular docking analysis of phyto-ligands with multidrug resistant ß-lactamases of Staphylococcus aureus. Trends Bioinfo;4:23-34.